If you’ve already registered, please click here to log in to the webcast.

The identification of reliable diagnostic and prognostic biomarkers is crucial for improving early detection and guiding personalized treatment of mesothelioma, an aggressive cancer with a poor prognosis. While current approaches to mesothelioma diagnosis and monitoring are limited, recent research has highlighted the potential of long noncoding RNAs (lncRNAs) as a novel class of blood-based biomarkers that could revolutionize mesothelioma management. LncRNAs have emerged as promising biomarkers due to their unique expression patterns in various cancer types.

This webcast will explore the significance and clinical utility of plasma-derived lncRNA biomarkers for mesothelioma. An overview of the latest scientific evidence will highlight the promise of plasma lncRNA biomarkers to transform early detection and treatment monitoring for mesothelioma patients. Identifying these innovative clinical tools could lead to improved outcomes and quality of life for those affected by this devastating disease.

• The emerging role of lncRNAs as cancer biomarkers and their detection in liquid biopsies
• Studies demonstrating the diagnostic accuracy and prognostic value of specific plasma lncRNA signatures in mesothelioma
• Technological advancements enabling sensitive and specific detection of lncRNAs in plasma